{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:43:55Z","timestamp":1790772235205,"version":"4.1.0"},"reference-count":145,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T00:00:00Z","timestamp":1671840000000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.drudis.2021.07.015","type":"journal-article","created":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T05:36:55Z","timestamp":1627105015000},"page":"102-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["FVIII at the crossroad of coagulation, bone and immune biology: Emerging evidence of biological activities beyond hemostasis"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6294-4299","authenticated-orcid":false,"given":"Marie","family":"Cad\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Mu\u00f1oz-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Babuty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Fouassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Francoise","family":"Heymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Monahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Heymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2021.07.015_b0005","first-page":"727","article-title":"The diagnosis and management of congenital hemophilia","volume":"38","author":"Carcao","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.drudis.2021.07.015_b0010","doi-asserted-by":"crossref","first-page":"17773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias \u2013 from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.07.015_b0015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/MBC.0b013e328343f873","article-title":"Molecular characterization of female hemophilia A by multiplex ligation-dependent probe amplification analysis and X-chromosome inactivation study","volume":"22","author":"Song","year":"2011","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.drudis.2021.07.015_b0020","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1182\/blood.V92.11.3983","article-title":"The life cycle of coagulation factor VIII in view of its structure and function","volume":"11","author":"Lenting","year":"1998","journal-title":"Blood"},{"issue":"02","key":"10.1016\/j.drudis.2021.07.015_b0025","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1055\/s-0038-1657137","article-title":"Activation of human coagulation factor VIII by activated factor X, the common product of the intrinsic and the extrinsic pathway of blood coagulation","volume":"47","author":"Mertens","year":"1982","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.drudis.2021.07.015_b0030","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/blood-2017-02-767079","article-title":"Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex","volume":"14","author":"Kamikubo","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.07.015_b0035","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2016-04-713289","article-title":"Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A","volume":"16","author":"Pipe","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.drudis.2021.07.015_b0040","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Subcommittee on Factor VIII, Factor IX and rare coagulation disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostatis. Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.drudis.2021.07.015_b0045","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/17474086.2020.1775576","article-title":"Prophylaxis for hemophilia A without inhibitors: treatment options and considerations","volume":"13","author":"Valentino","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"10040","key":"10.1016\/j.drudis.2021.07.015_b0050","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2021.07.015_b0055","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/203312a0","article-title":"High-potency antihaemophilic factor concentrate prepared from cryiglobukin precipitate","volume":"203","author":"Pool","year":"1964","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.drudis.2021.07.015_b0060","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.drudis.2021.07.015_b0065","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1111\/jth.12929","article-title":"Half-life extended factor VIII for the treatment of hemophilia A","volume":"13","author":"Tiede","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.drudis.2021.07.015_b0070","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2011-09-382846","article-title":"Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients","volume":"119","author":"Powell","year":"2012","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.drudis.2021.07.015_b0075","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.07.015_b0080","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1182\/blood.2019001292","article-title":"BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice","volume":"135","author":"Chhabra","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.drudis.2021.07.015_b0085","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","article-title":"BIVV001 fusion protein as Factor VIII replacement therapy for hemophilia A","volume":"383","author":"Konkle","year":"2020","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.drudis.2021.07.015_b0090","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-Factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.07.015_b0095","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2018-07-820720","article-title":"Update on clinical gene therapy for hemophilia","volume":"5","author":"Perrin","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.drudis.2021.07.015_b0100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/rth2.12177","article-title":"Adenovirus-associated antibodies in UK cohort of hemophilia patients: a seroprevalence study of the presence of adenovirus-associated virus vector-serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia A","volume":"3","author":"Stanford","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"21","key":"10.1016\/j.drudis.2021.07.015_b0105","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of Factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"S3","key":"10.1016\/j.drudis.2021.07.015_b0110","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/hae.14077","article-title":"Inhibitors \u2013 recent insights","volume":"27","author":"Pratt","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.drudis.2021.07.015_b0115","first-page":"958","article-title":"Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis","volume":"5","author":"Marcucci","year":"2015","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.drudis.2021.07.015_b0120","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1111\/hae.14132","article-title":"Management of previously untreated patients with severe haemophilia A preferentially treated with recombinant factor VIII products: two French centres\u2019 real-life experience","volume":"26","author":"Drillaud","year":"2020","journal-title":"Haemophilia"},{"issue":"10","key":"10.1016\/j.drudis.2021.07.015_b0125","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nature Med"},{"issue":"5","key":"10.1016\/j.drudis.2021.07.015_b0130","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nature Med"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.015_b0135","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12185-018-2548-6","article-title":"Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia","volume":"111","author":"Chowdary","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.drudis.2021.07.015_b0140","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2516.2008.01963.x","article-title":"Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia","volume":"15","author":"Gerstner","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.drudis.2021.07.015_b0145","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.blre.2018.05.002","article-title":"Increased bone resorption in hemophilia","volume":"33","author":"Rodriguez-Merchan","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.drudis.2021.07.015_b0150","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/hae.13986","article-title":"Biomarkers of bone disease in persons with hemophilia","volume":"27","author":"Goldscheitter","year":"2021","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.drudis.2021.07.015_b0155","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/bjh.13312","article-title":"Increased fracture rates in people with haemophilia: a 10-year single institution retrospective analysis","volume":"170","author":"Gay","year":"2015","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.drudis.2021.07.015_b0160","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.injury.2015.06.034","article-title":"Epidemiology of fractures in patients with haemophilia","volume":"46","author":"Caviglia","year":"2015","journal-title":"Injury"},{"key":"10.1016\/j.drudis.2021.07.015_b0165","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2516.2008.01912.x","article-title":"Long-term prophylaxis in severe haemophilia seems to preserve bone mineral density","volume":"15","author":"Khawaji","year":"2009","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.drudis.2021.07.015_b0170","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/hae.13917","article-title":"Effect of low-dose factor VIII prophylaxis therapy on bone mineral density and 25(OH) vitamin D level in children with severe haemophilia A","volume":"26","author":"Gamal Andrawes","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.drudis.2021.07.015_b0175","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1538-7836.2011.04207.x","article-title":"Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties","volume":"9","author":"Benslimane-Ahmin","year":"2011","journal-title":"J Thromb Haemos"},{"issue":"18","key":"10.1016\/j.drudis.2021.07.015_b0180","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1007\/s00018-007-7104-0","article-title":"RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases","volume":"64","author":"Baud\u2019huin","year":"2007","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"10.1016\/j.drudis.2021.07.015_b0185","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.cytogfr.2013.06.001","article-title":"Osteoprotegerin: multiple partners for multiple functions","volume":"24","author":"Baud\u2019huin","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"10.1016\/j.drudis.2021.07.015_b0190","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/jcp.20354","article-title":"Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor","volume":"204","author":"Zannettino","year":"2005","journal-title":"J Cell Physiol"},{"issue":"46","key":"10.1016\/j.drudis.2021.07.015_b0195","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.M109.030312","article-title":"Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival","volume":"284","author":"Baud\u2019huin","year":"2009","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.015_b0200","first-page":"956","article-title":"Characterization of the interaction between von Willbrand factor and osteoprotegerin","volume":"5","author":"Shahbazi","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.015_b0205","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1365-2141.2012.09101.x","article-title":"Decreased bone density and bone strength in a mouse model of severe factor VIII deficiency","volume":"158","author":"Liel","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.drudis.2021.07.015_b0210","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/hae.12195","article-title":"The bone disease associated with factor VIII deficiency in mice is secondary to increased bone resorption","volume":"19","author":"Recht","year":"2013","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.015_b0215","doi-asserted-by":"crossref","first-page":"14428","DOI":"10.1038\/s41598-019-50787-9","article-title":"Hemophilia A and B mice, but not VWF\u2013\/\u2013 mice, display bone defects in congenital development and remodeling after injury","volume":"9","author":"Taves","year":"2019","journal-title":"Scientific Rep"},{"issue":"5","key":"10.1016\/j.drudis.2021.07.015_b0220","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/hae.12399","article-title":"Joint bleeding in factor VIII deficient mice causes an acute loss of trabecular bone and calcification of joint soft tissues which is prevented with aggressive factor replacement","volume":"20","author":"Lau","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.drudis.2021.07.015_b0225","first-page":"3661","article-title":"Factor VIII plays a direct role in osteoblast development","volume":"130","author":"Larson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.07.015_b0230","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1182\/bloodadvances.2018027557","article-title":"Reduced bone formation in males and increased bone resorption in females drive bone loss in hemophilia A mice","volume":"3","author":"Weitzmann","year":"2019","journal-title":"Blood Adv"},{"issue":"6\u20137","key":"10.1016\/j.drudis.2021.07.015_b0235","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.biocel.2007.12.003","article-title":"Protease-activated receptors in the musculoskeletal system","volume":"40","author":"Mackie","year":"2008","journal-title":"Int J Biochem Cell Biol"},{"issue":"5","key":"10.1016\/j.drudis.2021.07.015_b0240","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.bone.2008.12.031","article-title":"Thrombin-stimulated growth factor and cytokine expression in osteoblasts is mediated by protease-activated receptor-1 and prostanoids","volume":"44","author":"Pagel","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.drudis.2021.07.015_b0245","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood-2012-08-447458","article-title":"A novel role for factor VIII and thrombin\/PAR1 in regulating hematopoiesis and its interplay with the bone structure","volume":"122","author":"Aronovich","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.07.015_b0250","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bone.2014.11.004","article-title":"Thrombin receptor deficiency leads to a high bone mass phenotype by decreasing the RANKL\/OPG ratio","volume":"72","author":"Tudpor","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.drudis.2021.07.015_b0255","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1182\/blood-2018-99-118989","article-title":"The role of thrombin deficiency on skeletal health","volume":"132","author":"Taylor","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.drudis.2021.07.015_b0260","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.bone.2011.11.023","article-title":"Proteinase-activated receptor-2 is required for normal osteoblast and osteoclast differentiation during skeletal growth and repair","volume":"50","author":"Georgy","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.drudis.2021.07.015_b0265","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bonr.2017.12.001","article-title":"The effect of oral dabigatran etelixate on bone density, strength, and microstructure in healthy mice","volume":"8","author":"Brent","year":"2017","journal-title":"Bone Rep"},{"issue":"4","key":"10.1016\/j.drudis.2021.07.015_b0270","doi-asserted-by":"crossref","first-page":"e014510","DOI":"10.1161\/JAHA.119.014510","article-title":"Risk of osteoporosis in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants or warfarin","volume":"9","author":"Huang","year":"2020","journal-title":"Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.drudis.2021.07.015_b0275","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/03008207.2016.1220942","article-title":"Rivaroxaban significantly inhibits the stimulatory effects of bone-modulating hormones: in vitro study of primary female osteoblasts","volume":"58","author":"Somjen","year":"2017","journal-title":"Connect Tissue Res"},{"issue":"6","key":"10.1016\/j.drudis.2021.07.015_b0280","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/bjh.14799","article-title":"Immune status of patients with haemophilia A before exposure to factor VIII: first results from the HEMFIL study","volume":"178","author":"Jardim","year":"2017","journal-title":"Br J Heamatol"},{"issue":"3","key":"10.1016\/j.drudis.2021.07.015_b0285","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.thromres.2013.10.039","article-title":"Hemarthrosis in hemophilic mice results in alterations in M1\u2013M2 monocyte\/macrophage polarization","volume":"133","author":"Nieuwenhuizen","year":"2014","journal-title":"Thrombosis Res"},{"issue":"9","key":"10.1016\/j.drudis.2021.07.015_b0290","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1002\/jcp.26429","article-title":"Macrophage plasticity, polarization, and function in health and disease","volume":"233","author":"Shapouri\u2010Moghaddam","year":"2018","journal-title":"J Cell Physiol"},{"issue":"02","key":"10.1016\/j.drudis.2021.07.015_b0295","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-0038-1676796","article-title":"Macrophage polarization is deregulated in haemophilia","volume":"119","author":"Knowles","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.drudis.2021.07.015_b0300","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1182\/bloodadvances.2018024497","article-title":"Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization","volume":"2","author":"Kis-Toth","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.drudis.2021.07.015_b0305","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1097\/HS9.0000000000000330","article-title":"Factor VIII Fc fusion protein but not FVIII drives human monocyte-derived dendritic cell activation via Fc\u03b3RIIa","volume":"4","author":"Kannicht","year":"2020","journal-title":"Hemasphere"},{"issue":"06","key":"10.1016\/j.drudis.2021.07.015_b0310","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1055\/s-0038-1641755","article-title":"Vascular permeability and remodelling coincide with inflammatory and reparative processes after joint bleeding in factor VIII-deficient mice","volume":"118","author":"Cooke","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.drudis.2021.07.015_b0315","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood-2016-08-734053","article-title":"Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis","volume":"129","author":"Sun","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.07.015_b0320","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/jth.14567","article-title":"Mechanism of vascular permeability and remodeling associated with hemarthrosis in factor VIII-deficient mice","volume":"17","author":"Cooke","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.drudis.2021.07.015_b0325","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/jth.13936","article-title":"Early cellular interactions and immune transcriptome profiles in human factor VIII-exposed hemophilia A mice","volume":"16","author":"Lai","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.drudis.2021.07.015_b0330","article-title":"Factor Xa inhibitor rivaroxaban suppresses experimental abdominal aortic aneurysm progression via attenuating aortic inflammation","volume":"21","author":"Ding","year":"2020","journal-title":"Vasc Pharmacol"},{"issue":"8","key":"10.1016\/j.drudis.2021.07.015_b0335","doi-asserted-by":"crossref","first-page":"e012195","DOI":"10.1161\/JAHA.119.012195","article-title":"Rivaroxaban, a direct factor Xa inhibitor, ameliorates hypertensive renal damage through inhibition of the inflammatory response mediated by protease-activated receptor pathway","volume":"8","author":"Ichikawa","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.drudis.2021.07.015_b0340","first-page":"2335","article-title":"Direct factor Xa inhibition attenuates acute lung injury progression via modulation of the PAR-2\/NF-kappaB signaling pathway","volume":"10","author":"Shi","year":"2018","journal-title":"Am J Transl Res"},{"issue":"16","key":"10.1016\/j.drudis.2021.07.015_b0345","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/CIRCULATIONAHA.118.033544","article-title":"Protease-activated receptor-2 plays a critical role in vascular inflammation and atherosclerosis in apolipoprotein E-deficient mice","volume":"138","author":"Hara","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.drudis.2021.07.015_b0350","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.atherosclerosis.2015.03.023","article-title":"Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice","volume":"242","author":"Hara","year":"2015","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.drudis.2021.07.015_b0355","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/art.22423","article-title":"Expression and proinflammatory role of proteinase-activated receptor 2 in rheumatoid synovium: ex vivo studies using a novel proteinase-activated receptor 2 antagonist","volume":"56","author":"Kelso","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.drudis.2021.07.015_b0360","first-page":"2326","article-title":"Factor Xa induces pro-inflammatory cytokine expression in RAW 264.7 macrophages via protease-activated receptor-2 activation","volume":"7","author":"Zuo","year":"2015","journal-title":"Am J Trans Res"},{"issue":"6","key":"10.1016\/j.drudis.2021.07.015_b0365","doi-asserted-by":"crossref","first-page":"9799","DOI":"10.1002\/jcb.28260","article-title":"PAR2 promotes M1 macrophage polarization and inflammation via FOXO1 pathway","volume":"120","author":"Chen","year":"2019","journal-title":"J Cell Biochem"},{"issue":"11","key":"10.1016\/j.drudis.2021.07.015_b0370","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1136\/annrheumdis-2015-208268","article-title":"Proteinase-activated receptor-2 modulates OA-related pain, cartilage and bone pathology","volume":"75","author":"Huesa","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.drudis.2021.07.015_b0375","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.molimm.2019.08.004","article-title":"Triggering of protease-activated receptors (PARs) induces alternative M2 macrophage polarization with impaired plasticity","volume":"114","author":"Garc\u00eda-Gonz\u00e1lez","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1016\/j.drudis.2021.07.015_b0380","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.3389\/fimmu.2020.01737","article-title":"Microtomography of immune cells in osteoporosis and bone lesions by endocrine disruptors","volume":"11","author":"Toni","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2021.07.015_b0385","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1182\/blood.2019000190","article-title":"Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients","volume":"134","author":"Swystun","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.07.015_b0390","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1111\/j.1538-7836.2009.03571.x","article-title":"Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia","volume":"7","author":"Navarrete","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.drudis.2021.07.015_b0395","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood-2008-01-133181","article-title":"Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo","volume":"112","author":"Van Schooten","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.drudis.2021.07.015_b0400","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.4049\/jimmunol.1700373","article-title":"A consensus definitive classification of scavenger receptors and their roles in health and disease","volume":"198","author":"PrabhuDas","year":"2017","journal-title":"J Immunol"},{"issue":"50","key":"10.1016\/j.drudis.2021.07.015_b0405","doi-asserted-by":"crossref","first-page":"26035","DOI":"10.1074\/jbc.M116.754622","article-title":"Evidence that factor VIII forms a bivalent complex with the low density lipoprotein (LDL) receptor-related protein 1 (LRP1): identification of cluster IV on LRP1 as the major binding site","volume":"291","author":"Young","year":"2016","journal-title":"J Biol Chem"},{"issue":"53","key":"10.1016\/j.drudis.2021.07.015_b0410","doi-asserted-by":"crossref","first-page":"37685","DOI":"10.1074\/jbc.274.53.37685","article-title":"Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism","volume":"274","author":"Saenko","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2021.07.015_b0415","doi-asserted-by":"crossref","first-page":"23734","DOI":"10.1074\/jbc.274.34.23734","article-title":"The light chain of FVIII comprises a binding site for low density lipoprotein receptor-related protein","volume":"274","author":"Lenting","year":"1999","journal-title":"J Biol Chem"},{"issue":"15","key":"10.1016\/j.drudis.2021.07.015_b0420","doi-asserted-by":"crossref","first-page":"11970","DOI":"10.1074\/jbc.M008046200","article-title":"Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein","volume":"276","author":"Sarafanov","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2021.07.015_b0425","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1182\/blood-2002-07-2081","article-title":"Elevate plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency","volume":"101","author":"Bovenschen","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.07.015_b0430","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood-2004-11-4230","article-title":"LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo","volume":"106","author":"Bovenschen","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.drudis.2021.07.015_b0435","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1021\/bi5011688","article-title":"Cluster III of low-density lipoprotein receptor-related protein 1 binds activated blood coagulation factor VIII","volume":"54","author":"Kurasawa","year":"2015","journal-title":"Biochem"},{"key":"10.1016\/j.drudis.2021.07.015_b0440","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.bbrc.2020.01.065","article-title":"Knockdown of Lrp1 in RAW264 cells inhibits osteoclast differentiation and osteoclast-osteoblast interactions in vitro","volume":"523","author":"Kohara","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2021.07.015_b0445","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41413-017-0006-3","article-title":"Lrp1 in osteoblasts controls osteoclast activity and protects against osteoporosis by limiting PDGF-RANKL signaling","volume":"6","author":"Bartelt","year":"2018","journal-title":"Bone Res"},{"key":"10.1016\/j.drudis.2021.07.015_b0450","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1210\/me.2003-0456","article-title":"The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells","volume":"18","author":"Grey","year":"2004","journal-title":"Mol Endocrinol"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.015_b0455","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1038\/s41467-018-07666-0","article-title":"Macrophage cells secrete factors including LRP1 that orchestrate the rejuvenation of bone repair in mice","volume":"9","author":"Vi","year":"2018","journal-title":"Nature Commun"},{"key":"10.1016\/j.drudis.2021.07.015_b0460","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/jth.14355","article-title":"Factor VIII with a 237 amino acid B-domain has an extended half-life in F8-knockout mice","volume":"17","author":"Bloem","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.drudis.2021.07.015_b0465","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/j.1538-7836.2005.01389.x","article-title":"The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor","volume":"3","author":"Bovenschen","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.drudis.2021.07.015_b0470","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1365-2516.2009.02026.x","article-title":"Functional roles of the factor VIII B domain","volume":"15","author":"Pipe","year":"2009","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.drudis.2021.07.015_b0475","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nm1760","article-title":"The Ashwell receptor mitigates the lethal coagulopathy of sepsis","volume":"14","author":"Grewal","year":"2008","journal-title":"Nature Med"},{"issue":"10","key":"10.1016\/j.drudis.2021.07.015_b0480","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.4049\/jimmunol.167.10.5767","article-title":"Immature human dendritic cells express asialoglycoprotein receptor isoforms for efficient receptor-mediated endocytosis","volume":"167","author":"Valladeau","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2021.07.015_b0485","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1046\/j.1365-2141.2002.03808.x","article-title":"Human Siglec-5: tissue distribution, novel isoform and domain specificities for sialic acid-dependent ligand interactions","volume":"119","author":"Connoly","year":"2002","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.drudis.2021.07.015_b0490","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.3324\/haematol.2012.063297","article-title":"Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5","volume":"97","author":"Pegon","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.drudis.2021.07.015_b0495","doi-asserted-by":"crossref","first-page":"37953","DOI":"10.1038\/srep37953","article-title":"Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity","volume":"6","author":"Pepin","year":"2016","journal-title":"Scientific Rep"},{"key":"10.1016\/j.drudis.2021.07.015_b0500","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1172\/JCI96400","article-title":"The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity","volume":"128","author":"Swystun","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2021.07.015_b0505","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1182\/blood-2015-02-624551","article-title":"Rare and low-frequency variants and their association with plasma levels of fibrinogen, FVII, FVIII, and VWF","volume":"126","author":"Huffman","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.015_b0510","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.bbrc.2014.11.068","article-title":"Tissue-specific splice variants of HARE\/Stabilin-2 are expressed in bone marrow, lymph node, and spleen","volume":"456","author":"Hare","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"10.1016\/j.drudis.2021.07.015_b0515","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/biom9080387","article-title":"Stabilin receptors: role as phosphatidyl serine receptors","volume":"9","author":"Park","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2021.07.015_b0520","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13256-020-02365-1","article-title":"Anal extraskeletal osteosarcoma in a man: a case report and review of the literature","volume":"14","author":"Saadaat","year":"2020","journal-title":"J Med Case Rep"},{"issue":"2","key":"10.1016\/j.drudis.2021.07.015_b0525","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00223-019-00552-x","article-title":"Ablation of stabilin-1 enhances bone-resorbing activity in osteoclasts in vitro","volume":"105","author":"Kim","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.drudis.2021.07.015_b0530","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1189\/jlb.0107052","article-title":"Stabilin-2 is involved in lymphocyte adhesion to the hepatic sinusoidal endothelium via the interaction with alphaMbeta2 integrin","volume":"82","author":"Jung","year":"2007","journal-title":"J Leukoc Biol"},{"issue":"8","key":"10.1016\/j.drudis.2021.07.015_b0535","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00109-008-0350-2","article-title":"DC-SIGN and L-SIGN: the SIGNs for infection","volume":"86","author":"Khoo","year":"2008","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.drudis.2021.07.015_b0540","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1182\/blood-2012-10-457507","article-title":"The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels","volume":"121","author":"Rydz","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.07.015_b0545","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/jth.14404","article-title":"The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent manner","volume":"17","author":"Swystun","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.drudis.2021.07.015_b0550","doi-asserted-by":"crossref","first-page":"100443","DOI":"10.1016\/j.imu.2020.100443","article-title":"Understand variability of COVID-19 through population and tissue variations in expression of SARS-CoV-2 host genes","volume":"21","author":"Chen","year":"2020","journal-title":"Informatics Med Unlocked"},{"key":"10.1016\/j.drudis.2021.07.015_b0555","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/CIRCULATIONAHA.109.869156","article-title":"Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium","volume":"121","author":"Smith","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2021.07.015_b0560","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/jth.14521","article-title":"The scavenger receptor SCARA5 is an endocytic receptor for von Willebrand factor expressed by littoral cells in the human spleen","volume":"17","author":"Swystun","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.drudis.2021.07.015_b0565","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.3892\/mmr.2016.4857","article-title":"Overexpression of SCARA-5 inhibits tumor proliferation and invasion in osteosarcoma via suppression of the FAK signaling pathway","volume":"13","author":"Wen","year":"2016","journal-title":"Mol Med Rep"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.015_b0570","doi-asserted-by":"crossref","first-page":"14833","DOI":"10.1038\/s41598-017-12512-2","article-title":"SCARA-5 plays a critical role in the commitment of mesenchymal stem cells to adipogenesis","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.drudis.2021.07.015_b0575","doi-asserted-by":"crossref","first-page":"514","DOI":"10.14336\/AD.2015.1206","article-title":"The role of bone marrow microenvironment in governing the balance between osteoblastogenesis and adipogenesis","volume":"7","author":"Li","year":"2016","journal-title":"Aging Dis"},{"issue":"6","key":"10.1016\/j.drudis.2021.07.015_b0580","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s40259-018-0315-0","article-title":"Bispecific antibody Emicizumab for haemophilia A: a breakthrough for patients with inhibitors","volume":"32","author":"Mahlangu","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.drudis.2021.07.015_b0585","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.drudis.2021.07.015_b0590","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1111\/jth.13811","article-title":"Effect of late prophylaxis in hemophilia on joint status: a randomized trial","volume":"15","author":"Manco-Johnson","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.drudis.2021.07.015_b0595","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/bloodadvances.2019001311","article-title":"Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the joint outcome continuation study","volume":"4","author":"Warren","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.drudis.2021.07.015_b0600","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1542\/peds.114.2.e177","article-title":"Reduced bone density among children with severe hemophilia","volume":"114","author":"Barnes","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.drudis.2021.07.015_b0605","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1182\/blood-2014-10-602060","article-title":"Premature changes in trabecular and cortical microarchitecture result in decreased bone strength in hemophilia","volume":"125","author":"Lee","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.drudis.2021.07.015_b0610","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1111\/hae.13516","article-title":"Low bone mineral density and associated factors in patients with haemophilia in Colombia","volume":"24","author":"Sossa Melo","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.drudis.2021.07.015_b0615","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2516.2011.02616.x","article-title":"Boys with haemophilia have low trabecular bone mineral density and sarcopenia, but normal bone strength at the radius","volume":"18","author":"Soucek","year":"2012","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.drudis.2021.07.015_b0620","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/10245330701383700","article-title":"Evaluation of bone mineral density in children with hemophilia: Mansoura University Children Hospital (MUCH) experience, Mansoura","volume":"12","author":"Abdelrazik","year":"2007","journal-title":"Egypt. Hematology"},{"issue":"6","key":"10.1016\/j.drudis.2021.07.015_b0625","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s12098-019-02855-1","article-title":"Serum sclerostin level and bone mineral density in pediatric hemophilic arthropathy","volume":"86","author":"El-Mikkawy","year":"2019","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.drudis.2021.07.015_b0630","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2141.2011.08639.x","article-title":"Hypercalciuria in children with haemophilia suggests primary skeletal pathology","volume":"153","author":"Ranta","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.drudis.2021.07.015_b0635","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1097\/MPH.0b013e3181e8cd40","article-title":"Bone status of children with hemophilia A assessed with quantitative ultrasound sonography (QUS) and dual energy X-ray absorptiometry (DXA)","volume":"32","author":"Christoforidis","year":"2010","journal-title":"J Pediatric Hematol Oncol"},{"issue":"03","key":"10.1016\/j.drudis.2021.07.015_b0640","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1160\/TH11-08-05563","article-title":"Reduced bone mineral density in patients with haemophilia A and B in Northern Greece","volume":"107","author":"Anagnostis","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.drudis.2021.07.015_b0645","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/MPH.0000000000001554","article-title":"Evaluation of bone mineral density in children with hemophilia: an observational case-control study","volume":"41","author":"Ashritha","year":"2019","journal-title":"J Pediatric Hematol Oncol"},{"key":"10.1016\/j.drudis.2021.07.015_b0650","first-page":"82","article-title":"Osteoporosis\/osteopenia and hemophilic arthropathy in severe hemophilic patients","volume":"15","author":"Naderi","year":"2012","journal-title":"Arch Iran Med"},{"issue":"4","key":"10.1016\/j.drudis.2021.07.015_b0655","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12288-013-0318-4","article-title":"Bone mineral density in hemophilia patients","volume":"30","author":"Roushan","year":"2014","journal-title":"Indian J Hematol Blood Transf"},{"key":"10.1016\/j.drudis.2021.07.015_b0660","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1756-185X.2009.01394.x","article-title":"Reduced bone density in individuals with severe hemophilia B","volume":"12","author":"Mansouritorghabeh","year":"2009","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"10.1016\/j.drudis.2021.07.015_b0665","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1365-2516.2005.01116.x","article-title":"Bone properties and muscle strength of young haemophilia patients","volume":"11","author":"Falk","year":"2005","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.drudis.2021.07.015_b0670","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/hae.13611","article-title":"Usefulness of bone microarchitectural and geometric DXA-derived parameters in haemophilic patients","volume":"24","author":"Ulivieri","year":"2018","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.015_b0675","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1365-2516.2012.02899.x","article-title":"Hypovitaminosis D and osteopenia\/osteoporosis in a haemophilia population: a study in HCV\/HIV or HCV infected patients","volume":"19","author":"Linari","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.drudis.2021.07.015_b0680","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1365-2516.2010.02439.x","article-title":"Orozco-Alcala J. Bone turnover markers and bone mineral density in children with haemophilia","volume":"17","author":"Tiacuilo-Parra","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.drudis.2021.07.015_b0685","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1365-2516.2010.02423.x","article-title":"Bone density and health-related quality of life in adult patients with severe haemophilia","volume":"17","author":"Khawaji","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.drudis.2021.07.015_b0690","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1111\/hae.13836","article-title":"Decreased bone mineral density and associated factors in severe haemophilia A patients: a case-control study","volume":"25","author":"Ekinci","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.drudis.2021.07.015_b0695","doi-asserted-by":"crossref","DOI":"10.1177\/1076029619861689","article-title":"Osteoporosis in patients with hemophilia: single-center results from a middle-income country","volume":"25","author":"Sahin","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.drudis.2021.07.015_b0700","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/MPH.0000000000001394","article-title":"Impact of prophylaxis on bone mineral metabolism in children with hemophilia","volume":"41","author":"Culha","year":"2019","journal-title":"J Pediatric Hematol Oncol"},{"issue":"2","key":"10.1016\/j.drudis.2021.07.015_b0705","doi-asserted-by":"crossref","first-page":"206","DOI":"10.17305\/bjbms.2018.2335","article-title":"Evaluation of bone mineral density (BMD) and indicators of bone turnover in patients with hemophilia","volume":"18","author":"Dagli","year":"2018","journal-title":"Bos J Basic Med Sci"},{"key":"10.1016\/j.drudis.2021.07.015_b0710","first-page":"59","article-title":"Evaluation of bone mineral density and related parameters in patients with haemophilia: a single center cross-sectional study","volume":"27","author":"Unal","year":"2017","journal-title":"Am J Blood Res"},{"key":"10.1016\/j.drudis.2021.07.015_b0715","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2516.2011.02587.x","article-title":"Evaluation of bone mineral density in Turkish children with severe haemophilia A: Ankara hospital experience","volume":"18","author":"Alioglu","year":"2015","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.015_b0720","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/hae.12565","article-title":"A case-control study assessing bone mineral density in severe haemophilia A in the UK","volume":"21","author":"Wells","year":"2015","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.015_b0725","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/hae.12240","article-title":"Bone density in haemophilia: a single institutional cross-sectional study","volume":"20","author":"Kempton","year":"2014","journal-title":"Haemophilia"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621003214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621003214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:57:08Z","timestamp":1761224228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644621003214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":145,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1359644621003214"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2021.07.015","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FVIII at the crossroad of coagulation, bone and immune biology: Emerging evidence of biological activities beyond hemostasis","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2021.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}